A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Concizumab (Primary) ; Turoctocog alfa
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms Explorer 5
- Sponsors Novo Nordisk
- 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2017 Planned End Date changed from 8 Aug 2019 to 9 Aug 2019.
- 17 Aug 2017 Status changed from not yet recruiting to recruiting.